Advertisement
Screener

Ovid Therapeutics Inc. (OVID) Financing Cash Flow

2.8 / 5 stars · 68/120 Roast Me

Ovid Therapeutics Inc. Financing Cash Flow

Ovid Therapeutics Inc. (OVID) reported Financing Cash Flow of $110.58 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.

Financial Statements › Cash Flow › Financing Activities

us-gaap:NetCashProvidedByUsedInFinancingActivities · last filed 2026-08-13

  • Ovid Therapeutics Inc. net cash provided by (used in) financing activities for the quarter ending 2026-06-30 was $21.60M.
  • Ovid Therapeutics Inc. net cash provided by (used in) financing activities for the quarter ending 2026-03-31 was $88.98M, a 684376.92% increase year-over-year.
  • Ovid Therapeutics Inc. net cash provided by (used in) financing activities for the quarter ending 2025-12-31 was $75.18M.
  • Ovid Therapeutics Inc. net cash provided by (used in) financing activities for the quarter ending 2025-09-30 was $15.00K, a 60.53% decline year-over-year.
  • Ovid Therapeutics Inc. net cash provided by (used in) financing activities for fiscal 2025 was $75.21M, a 11991.16% increase from fiscal 2024.
  • Ovid Therapeutics Inc. net cash provided by (used in) financing activities for fiscal 2024 was $622.00K, a 97.96% decline from fiscal 2023.
  • Ovid Therapeutics Inc. net cash provided by (used in) financing activities for fiscal 2023 was $30.54M, a 16802.10% increase from fiscal 2022.
  • Ovid Therapeutics Inc. net cash provided by (used in) financing activities for fiscal 2022 was $180.66K, a 80.02% decline from fiscal 2021.
Period endNet Cash Provided by (Used in) Financing Activities 3 monthNet Cash Provided by (Used in) Financing Activities 3 month as first filedNet Cash Provided by (Used in) Financing Activities 6 monthNet Cash Provided by (Used in) Financing Activities 6 month as first filedNet Cash Provided by (Used in) Financing Activities 9 monthNet Cash Provided by (Used in) Financing Activities 9 month as first filedNet Cash Provided by (Used in) Financing Activities 12 monthNet Cash Provided by (Used in) Financing Activities 12 month as first filed
2026-06-30$21.60M
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13
$110.58M
10-Q · filed 2026-08-13
$185.76M
derived: sum of 3 quarters · filed 2026-08-13
$185.78M
derived: sum of 4 quarters · filed 2026-08-13
2026-03-31$88.98M
10-Q · filed 2026-05-12
$164.16M
derived: sum of 2 quarters · filed 2026-05-12
$164.18M
derived: sum of 3 quarters · filed 2026-05-12
$164.18M
derived: sum of 4 quarters · filed 2026-08-13
2025-12-31$75.18M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-18
$75.19M
derived: sum of 2 quarters · filed 2026-03-18
$75.19M
derived: sum of 3 quarters · filed 2026-08-13
$75.21M
10-K · filed 2026-03-18
2025-09-30$15.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12
$15.00K
derived: sum of 2 quarters · filed 2026-08-13
$28.00K
10-Q · filed 2025-11-12
$28.00K
derived: sum of 4 quarters · filed 2026-08-13
2025-06-30$0.00
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13
$13.00K
10-Q · filed 2026-08-13
$13.00K
derived: sum of 3 quarters · filed 2026-08-13
$51.00K
derived: sum of 4 quarters · filed 2026-08-13
2025-03-31$13.00K
10-Q · filed 2026-05-12
$13.00K
derived: sum of 2 quarters · filed 2026-05-12
$51.00K
derived: sum of 3 quarters · filed 2026-05-12
$407.00K
derived: sum of 4 quarters · filed 2026-05-12
2024-12-31$0.00
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-18
$38.00K
derived: sum of 2 quarters · filed 2026-03-18
$394.00K
derived: sum of 3 quarters · filed 2026-03-18
$622.00K
10-K · filed 2026-03-18
2024-09-30$38.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12
$394.00K
derived: sum of 2 quarters · filed 2025-11-12
$622.00K
10-Q · filed 2025-11-12
$30.66M
derived: sum of 4 quarters · filed 2025-11-12
2024-06-30$356.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13
$584.00K
10-Q · filed 2025-08-13
$30.62M
derived: sum of 3 quarters · filed 2025-08-13
$30.84M
derived: sum of 4 quarters · filed 2025-08-13
2024-03-31$228.00K
10-Q · filed 2025-05-13
$30.26M
derived: sum of 2 quarters · filed 2025-05-13
$30.48M
derived: sum of 3 quarters · filed 2025-05-13
$30.70M
derived: sum of 4 quarters · filed 2025-05-13
2023-12-31$30.03M
derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-11
$30.26M
derived: sum of 2 quarters · filed 2025-03-11
$30.47M
derived: sum of 3 quarters · filed 2025-03-11
$30.54M
10-K · filed 2025-03-11
$30.54M
10-K · filed 2024-03-08
2023-09-30$224.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12
$435.00K
derived: sum of 2 quarters · filed 2024-11-12
$502.00K
10-Q · filed 2024-11-12
$501.81K
10-Q · filed 2023-11-03
$458.40K
derived: sum of 4 quarters · filed 2024-11-12
2023-06-30$211.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13
$278.00K
10-Q · filed 2024-08-13
$278.09K
10-Q · filed 2023-08-04
$234.40K
derived: sum of 3 quarters · filed 2024-08-13
$316.03K
derived: sum of 4 quarters · filed 2024-08-13
2023-03-31$67.00K
10-Q · filed 2024-05-14
$66.99K
10-Q · filed 2023-05-05
$23.40K
derived: sum of 2 quarters · filed 2024-05-14
$105.03K
derived: sum of 3 quarters · filed 2024-05-14
$214.58K
derived: sum of 4 quarters · filed 2024-05-14
2022-12-31-$43.60K
derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-08
$38.03K
derived: sum of 2 quarters · filed 2024-03-08
$147.58K
derived: sum of 3 quarters · filed 2024-03-08
$180.66K
10-K · filed 2024-03-08
2022-09-30$81.63K
derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-03
$191.18K
derived: sum of 2 quarters · filed 2023-11-03
$224.26K
10-Q · filed 2023-11-03
$333.44K
derived: sum of 4 quarters · filed 2023-11-03
2022-06-30$109.55K
derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-04
$142.63K
10-Q · filed 2023-08-04
$251.81K
derived: sum of 3 quarters · filed 2023-08-04
$800.86K
derived: sum of 4 quarters · filed 2023-08-04
2022-03-31$33.08K
10-Q · filed 2023-05-05
$142.26K
derived: sum of 2 quarters · filed 2023-05-05
$691.31K
derived: sum of 3 quarters · filed 2023-05-05
$807.50K
derived: sum of 4 quarters · filed 2023-05-05
2021-12-31$109.18K
derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-13
$658.23K
derived: sum of 2 quarters · filed 2023-03-13
$774.42K
derived: sum of 3 quarters · filed 2023-03-13
$904.08K
10-K · filed 2023-03-13
2021-09-30$549.05K
derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08
$665.24K
derived: sum of 2 quarters · filed 2022-11-08
$794.90K
10-Q · filed 2022-11-08
$562.42K
derived: sum of 4 quarters · filed 2022-11-08
2021-06-30$116.19K
derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09
$245.85K
10-Q · filed 2022-08-09
$13.37K
derived: sum of 3 quarters · filed 2022-08-09
$47.13M
derived: sum of 4 quarters · filed 2022-08-09
2021-03-31$129.66K
10-Q · filed 2022-05-10
-$102.82K
derived: sum of 2 quarters · filed 2022-05-10
$47.02M
derived: sum of 3 quarters · filed 2022-05-10
$47.19M
derived: sum of 4 quarters · filed 2022-05-10
2020-12-31-$232.48K
derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-15
$46.89M
derived: sum of 2 quarters · filed 2022-03-15
$47.06M
derived: sum of 3 quarters · filed 2022-03-15
$47.07M
10-K · filed 2022-03-15
2020-09-30$47.12M
derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10
$47.29M
derived: sum of 2 quarters · filed 2021-11-10
$47.30M
10-Q · filed 2021-11-10
$103.19M
derived: sum of 4 quarters · filed 2021-11-10
2020-06-30$169.31K
derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-16
$184.84K
10-Q · filed 2021-08-16
$56.07M
derived: sum of 3 quarters · filed 2021-08-16
$56.13M
derived: sum of 4 quarters · filed 2021-08-16
2020-03-31$15.54K
10-Q · filed 2021-05-13
$55.90M
derived: sum of 2 quarters · filed 2021-05-13
$55.96M
derived: sum of 3 quarters · filed 2021-05-13
$55.57M
derived: sum of 4 quarters · filed 2021-05-13
2019-12-31$55.89M
derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-15
$55.95M
derived: sum of 2 quarters · filed 2021-03-15
$55.55M
derived: sum of 3 quarters · filed 2021-03-15
$86.54M
10-K · filed 2021-03-15
2019-09-30$58.79K
derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-13
-$333.09K
derived: sum of 2 quarters · filed 2020-11-13
$30.65M
10-Q · filed 2020-11-13
$30.65M
derived: sum of 4 quarters · filed 2020-11-13
2019-06-30-$391.88K
derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-10
$30.59M
10-Q · filed 2020-08-10
$30.59M
derived: sum of 3 quarters · filed 2020-08-10
$30.71M
derived: sum of 4 quarters · filed 2020-08-10
2019-03-31$30.99M
10-Q · filed 2020-05-07
$30.99M
derived: sum of 2 quarters · filed 2020-05-07
$31.10M
derived: sum of 3 quarters · filed 2020-05-07
$31.20M
derived: sum of 4 quarters · filed 2020-05-07
2018-12-31$2.00
derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-11
$112.04K
derived: sum of 2 quarters · filed 2020-03-11
$210.74K
derived: sum of 3 quarters · filed 2020-03-11
$286.14K
10-K · filed 2020-03-11
2018-09-30$112.04K
derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-08
$210.74K
derived: sum of 2 quarters · filed 2019-11-08
$286.14K
10-Q · filed 2019-11-08
$313.18K
derived: sum of 4 quarters · filed 2019-11-08
2018-06-30$98.70K
derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-07
$174.10K
10-Q · filed 2019-08-07
$201.14K
derived: sum of 3 quarters · filed 2019-08-07
-$524.51K
derived: sum of 4 quarters · filed 2019-08-07
2018-03-31$75.40K
10-Q · filed 2019-05-07
$102.44K
derived: sum of 2 quarters · filed 2019-05-07
-$623.21K
derived: sum of 3 quarters · filed 2019-05-07
2017-12-31$27.04K
derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-07
-$698.62K
derived: sum of 2 quarters · filed 2019-03-07
$66.70M
10-K · filed 2019-03-07
2017-09-30-$725.66K
derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-08
$66.68M
10-Q · filed 2018-11-08
2017-06-30$67.40M
10-Q · filed 2018-08-09

Similar stocks

Stock NameCountryMarket CapPE Ratio
ASSEMBLY BIOSCIENCES, INC. (ASMB)United States$0.481B-13,053.96
CAPRICOR THERAPEUTICS, INC. (CAPR)United States$0.499B-10.81
PUMA BIOTECHNOLOGY, INC. (PBYI)United States$0.507B15.53
ARVINAS, INC. (ARVN)United States$0.510B58.38
MapLight Therapeutics, Inc. (MPLT)United States$0.459B-7.10
Evolus, Inc. (EOLS)United States$0.519B-13.32
CRESCENT BIOPHARMA, INC. (CBIO)United States$0.529B-5.20
Quoin Pharmaceuticals Ltd. (QNRX)$0.443B-17.85
CYPHERPUNK TECHNOLOGIES INC. (CYPH)United States$0.438B-75.63
Indaptus Therapeutics, Inc. (INDP)United States$0.537B